<DOC>
	<DOCNO>NCT01646294</DOCNO>
	<brief_summary>The purpose study investigate quickly extent YM178 absorb eliminate body , well tolerate , give three different tablet formulation ( sustained release ) day without food , compare result profile YM178 immediate release formulation take twice daily without food .</brief_summary>
	<brief_title>A Study Compare Actions Body Healthy Subjects Three Modified Release Formulations YM178 Under Fasted Fed Conditions With One Immediate Release Formulation YM178 Under Fasted Conditions</brief_title>
	<detailed_description>Subjects reside clinical research unit 3 period 11 day , washout period least 7 day treatment period . . Each subject treat multiple oral dos IR formulation ( b.i.d . ) fast condition , OCAS-F , OCAS-M OCAS-S formulation ( q.d . ) fast fed condition ( high fat breakfast ) . The study complete post-study visit 7 14 day discharge period 3 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Body weight 60.0 100.0 kg , BMI 18.0 30.0 kg/m2 Known suspected hypersensitivity βadrenergic receptor agonists constituent formulation use Clinically significant elevation serum creatinine liver enzymes evidence creatinine and/or abnormal serum bilirubin Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug Any clinically significant history upper gastrointestinal symptom 4 week prior first admission Research Unit Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic QTcB interval &gt; 430 msec screening ( mean QTcB two measurement &gt; 430msec ) Abnormal pulse rate measurement ( &lt; 40 &gt; 90 bpm ) prestudy visit subject rest supine position 5 min Abnormal blood pressure measurement take prestudy visit subject rest supine position 5 minute Positive orthostatic test screening i.e . symptom dizziness , lightheadedness etc . fall &gt; 20 mmHg systolic blood pressure 2 min standing ( outlined section 12.5 ) increase pulse rate ≥ 20 bpm History smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior first admission Research Unit . History drink 21 unit alcohol per week within 3 month prior first admission Research Unit Donation blood blood product ( 400 ml ) within 3 month prior first admission Research Unit plasmapheresis within 4 week precede start study Positive serology test HBsAg , HAV IgM , antiHCV antiHIV 1+2 Subject willing complete standard FDA high fat breakfast</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>YM178</keyword>
	<keyword>Modified release ( Oral Controlled Absorption System ( OCAS ) )</keyword>
	<keyword>Immediate release ( IR )</keyword>
	<keyword>Fasted condition</keyword>
	<keyword>Fed condition</keyword>
</DOC>